Market Cap 5.75M
Revenue (ttm) 27.38M
Net Income (ttm) -167.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -613.40%
Debt to Equity Ratio 0.00
Volume 118,703,398
Avg Vol 26,170,799
Day's Range N/A - N/A
Shares Out 154.59M
Stochastic %K 6%
Beta 1.91
Analysts Sell
Price Target $1.00

Company Profile

Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a rad...

Industry: Biotechnology
Sector: Healthcare
Phone: 617-461-4023
Address:
17 Drydock Avenue, Suite 17-401, Boston, United States
JonSn0w
JonSn0w Mar. 30 at 10:18 PM
1 · Reply
Gator5326
Gator5326 Mar. 30 at 8:24 PM
$AKTS https://aktisoncology.gcs-web.com/news-releases/news-release-details/aktis-oncology-announces-fda-clearance-investigational-new-drug
0 · Reply
Gator5326
Gator5326 Mar. 30 at 8:20 PM
$AKTS Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
0 · Reply
PHARMD09
PHARMD09 Mar. 30 at 6:43 PM
$AKTS check out these insider buys…. Buy now and you have a better average than the ones who spent over $100 million on this Lilly backed company.
0 · Reply
PHARMD09
PHARMD09 Mar. 29 at 10:12 PM
1 · Reply
Gator5326
Gator5326 Mar. 27 at 8:29 PM
$AKTS what happeNed?
1 · Reply
PHARMD09
PHARMD09 Mar. 27 at 7:57 PM
$AKTS why…
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 27 at 1:31 AM
RAD 101 Shows 90% Primary End Point Success in Brain Metastases Trial | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways $TLX $AKTS $CATX $RADX $LNTH https://www.targetedonc.com/view/rad-101-shows-90-primary-end-point-success-in-brain-metastases-trial
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 26 at 5:58 PM
$RADX $LNTH $AKTS $CATX Bottom line (straight, no fluff) RADX is a natural buyout because it: Fits Lantheus’ exact business model: Adds near-term revenue (RAD101) Provides theranostic pairs Leverages existing commercial + manufacturing infrastructure Is already strategically connected Is cheap relative to Lantheus deal history Helps defend against big pharma competition
0 · Reply
alsworthg
alsworthg Mar. 24 at 2:53 PM
0 · Reply
Latest News on AKTS
Aktis Oncology prices upsized US IPO at $18 per share

Jan 8, 2026, 9:20 PM EST - 2 months ago

Aktis Oncology prices upsized US IPO at $18 per share


Aktis Oncology files for US IPO as biotech listings rebound

Dec 19, 2025, 5:51 PM EST - 3 months ago

Aktis Oncology files for US IPO as biotech listings rebound


Aktis Oncology IPO Registration Document (S-1)

Dec 19, 2025, 4:02 PM EST - 3 months ago

Aktis Oncology IPO Registration Document (S-1)


JonSn0w
JonSn0w Mar. 30 at 10:18 PM
1 · Reply
Gator5326
Gator5326 Mar. 30 at 8:24 PM
$AKTS https://aktisoncology.gcs-web.com/news-releases/news-release-details/aktis-oncology-announces-fda-clearance-investigational-new-drug
0 · Reply
Gator5326
Gator5326 Mar. 30 at 8:20 PM
$AKTS Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
0 · Reply
PHARMD09
PHARMD09 Mar. 30 at 6:43 PM
$AKTS check out these insider buys…. Buy now and you have a better average than the ones who spent over $100 million on this Lilly backed company.
0 · Reply
PHARMD09
PHARMD09 Mar. 29 at 10:12 PM
1 · Reply
Gator5326
Gator5326 Mar. 27 at 8:29 PM
$AKTS what happeNed?
1 · Reply
PHARMD09
PHARMD09 Mar. 27 at 7:57 PM
$AKTS why…
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 27 at 1:31 AM
RAD 101 Shows 90% Primary End Point Success in Brain Metastases Trial | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways $TLX $AKTS $CATX $RADX $LNTH https://www.targetedonc.com/view/rad-101-shows-90-primary-end-point-success-in-brain-metastases-trial
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 26 at 5:58 PM
$RADX $LNTH $AKTS $CATX Bottom line (straight, no fluff) RADX is a natural buyout because it: Fits Lantheus’ exact business model: Adds near-term revenue (RAD101) Provides theranostic pairs Leverages existing commercial + manufacturing infrastructure Is already strategically connected Is cheap relative to Lantheus deal history Helps defend against big pharma competition
0 · Reply
alsworthg
alsworthg Mar. 24 at 2:53 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 24 at 2:46 PM
Webinar Registration - Zoom $RADX $AKTS $CATX $LNTH $TLX https://us02web.zoom.us/webinar/register/WN_Uy9zCUEhQUaMqC1rYG5Zhw#/registration
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 23 at 11:08 PM
$RADX Meets 90% news just broke on RAD101 $IMNM $AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 22 at 5:41 PM
Regarding RAD101 “tumors light up. We are at the cusp of a Theranostics revolution. $RADX $TLX $LNTH $AKTS
0 · Reply
PHARMD09
PHARMD09 Mar. 21 at 2:26 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 19 at 8:46 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 17 at 4:40 PM
RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets | CancerNetwork $RADX $CATX $AKTS $LNTH https://www.cancernetwork.com/view/rad-101-imaging-agent-achieves-concordance-with-mri-in-suspected-brain-mets
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 15 at 3:07 PM
B7-H3 https://www.linkedin.com/pulse/b7-h3-antibody-market-segmentation-size-trends-2026-2033-4agzf?utm_source=share&utm_medium=member_ios&utm_campaign=share_via $RADX $AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 4:43 PM
Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 1:20 PM
$LLY $NVS $RADX $LNTH $AKTS RADX only value play
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 3:20 AM
It’s possible RAD101 could be a $1 to $1.5 billion dollar brain imaging tracer. If it becomes the gold standard. Brain tumors in general live off fatty acids. Therefore that’s why it finds them and lights them up. But radiologist could potentially use it before stereotactic radiation because mri’s don’t always pick up very small brain Mets and definitely after stereotactic radiation because standard mri’s don’t work well after necrosis cause by the radiation laser (gamma or cyber knife). What’s interesting phase2a 10/10 and phase 2b 11/12. Also, there’s a major market for this in European and Asia as well. $RADX $LNTH $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 11 at 10:36 PM
Radiopharm: "Hold" As Theranostics Pipeline Has Several 2026 Milestones (NASDAQ:RADX) | Seeking Alpha $RADX $AKTS $NVS $LNTH https://seekingalpha.com/article/4881314-radiopharm-hold-as-theranostics-pipeline-has-several-2026-milestones
2 · Reply
RadioIsotope25
RadioIsotope25 Mar. 10 at 2:45 PM
Radiopharm Theranostics (ASX: RAD) KOL Webinar with Dr Ramji Rajendran - YouTube $RADX $CATX $AKTS $LNTH https://www.youtube.com/watch?v=d1lhPMFcrvY
0 · Reply